title: Hepatic trisegmentectomy for 29 patients with huge liver neoplasms.
abstract: OBJECTIVE
  To evaluate retrospectively the feasibility and effect of hepatic trisegmentectomy in therapy of huge neoplasms of the liver.
  
  
  METHODS
  From July 1993 to October 1999, 29 patients with huge hepatic neoplasms underwent hepatic trisegmentectomy. Of these, 23 patients suffered from primary liver cancer, 1 hepatic infiltration of gallbladder cancer, 1 metastasis of colon cancer, 1 hepatic angiosarcoma, 1 hepatic neurofibroma, and 2 huge liver cysts. Twenty-six patients were subjected to right trisegmentectomy and the rest 3 left trisegmentectomy. All trisegmentectomies were performed under normothermic interruption of the porta hepatis at single time and these interruptions lasted 15 to 40 minutes.
  
  
  RESULTS
  The relatively good effect was seen in our series. The 1-, 3-, 5-year survival rates for primary liver cancer patients were 63.6%, 36.4% and 27.3%, respectively. The survival period for the patients with hepatic infiltration of gallbladder cancer and liver metastasis of colon cancer was 6 months. Those with hepatic angiosarcoma, hepatic neurofibroma and huge liver cysts have been surviving 35, 26, 25 and 40 months, respectively. Major complications were noted in 5 patients, and one (3.4%, 1/29) died.
  
  
  CONCLUSIONS
  Hepatic trisegmentectomy is safe and effective in treatment of huge hepatic neoplasms if its indications and operative techniques are properly mastered.
authors: Liver Cancer Institute, Post & Telecom General Hospital, Department of Liver Surgery, 8th Clinical Hospital, Peking University, Beijing 100032, China. rlzhou@mail.bjmu.edu.cn
authors: Jing-An
authors: JA
authors: Rui
authors: Li
authors: L
authors: Zhou
authors: Shao-Bin
authors: SB
authors: Wang
authors: Shu-Guang
authors: SG
authors: Chen
authors: Xue
authors: X
authors: Wei
authors: Kai
authors: K
authors: Han
authors: Ning
authors: N
authors: Zhang
authors: Hai-Tao
authors: HT
authors: Zhao
authors: Xin
authors: X
authors: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003110:Colonic Neoplasms / Q000473:pathology; D003560:Cysts / Q000601:surgery; D005260:Female; D005706:Gallbladder Neoplasms / Q000473:pathology; D006394:Hemangiosarcoma / Q000601:surgery; D006498:Hepatectomy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009455:Neurofibroma / Q000601:surgery; D016019:Survival Analysis; D016896:Treatment Outcome